Skip to Main Content

Client Conversations: Interview with Matthew J. Maletta, Executive Vice President and Chief Legal Officer of Endo Pharmaceuticals

Date: 5 October 2020

In this episode, we interview Matthew Maletta, executive vice president and chief legal officer of Endo Pharmaceuticals. Prior to joining Endo in 2015, he served as vice president, associate general counsel, and corporate secretary of Allergan. He played a key role defending Allergan from an unsolicited takeover bid by Valeant Pharmaceuticals and Pershing Square Capital Management in 2014 and in the $70 billion acquisition of Allergan by Actavis in 2015. Listen to how Matthew was able to take advantage of the opportunities at a small firm and then move on to Skadden Arps, his role in a hostile takeover, and his role now as chief legal officer of Endo Pharmaceuticals.

Client Conversations features interviews with legal buyers, business partners, innovators and industry leaders to share our collaborative insights across the marketplace. We hope these discussions help you further understand the paths that outstanding professionals in the legal and business communities travel, learn about what they are looking for in their counselors, and the nuanced decision-making of business and legal leaders in various industries.

Contact us or catch-up on past episodes by visiting our Client Conversations program page

Subscribe to Client Conversations via your favorite podcast app to have our episodes delivered directly to you as they become available.

Craig W. Budner
Craig W. Budner
Dallas
Houston
View
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel